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Abstract
Leukaemia inhibitory factor (LIF) plays a critical role in
"stemness" versus "differentiation", a property that under‐
pins the core value of LIF as a therapeutic for both the
treatment of autoimmune disease and for promoting tissue
repair. This value can be realized using nano-engineering
technology, where a new generation of tools can, with
unprecedented ability, manipulate biological functions.
One striking example is the treatment of multiple sclerosis
(MS). The underpinning biology is the newly identified
LIF/IL-6 axis in T lymphocytes, which can tilt the behaviour
between immune tolerance versus immune attack. This
LIF/IL-6 axis is ideally suited to nanotherapeutic manipu‐
lation, given its inherent mechanistic simplicity of two
mutually opposing feed-forward loops that determine
either tolerogenic (LIF) or inflammatory (IL-6) immunity.
Using LIF that is formulated in biodegradable nanoparti‐
cles (LIF-NP) and targeted to CD4+ T cells, the axis is
harnessed towards immune tolerance. This has implica‐
tions for the treatment of autoimmune diseases, where the
clinical burden is immense. It encompasses more than 100
diseases and, in the USA alone, costs more than $100 billion
in direct health care costs annually. Other properties of LIF
include the promotion of healthy neuro-glial interactions
within the central nervous system (CNS), where, in
addition to MS, LIF-NP therapy is relevant to inflammatory
neurodegenerative diseases that represent a large and
increasing need within aging populations. Thirdly, LIF is a
reparative growth factor that can maintain genomic
plasticity. LIF-NP supports the use of stem cell-based
therapies in regenerative medicine plus augment thera‐
peutic benefits within the patient. These core properties of
LIF are greatly amplified in value by the advantage of being
formulated as nanoparticles, namely (i) targeted delivery,
(ii) exploitation of endogenous regulatory pathways and
(iii) creation of surrogate micro-stromal niches. We discuss
LIF-NP as a means to harness endogenous pathways for the
treatment of MS, both to reset immune self-tolerance and
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to promote repair of myelin that is required to support
health within the nervous system.
Keywords Nanomedicine, Inflammatory immune axis,
LIF-nanoparticles, Multiple sclerosis, Targeted delivery, In
vivo
1. Introduction
Nanomedicine is a new era in therapeutics, which has been
enabled by fundamental advances in biology combined
with progress in biocompatible nanotechnology. Nano‐
technology provides access to three highly desirable
therapeutic aims, namely (i) targeted delivery of drugs or
biologics, for example of cytotoxins to cancer cells, where
relatively high doses of the drug can be focused upon the
tumour with reduced off-target side effects; (ii) exploitation
of endogenous regulatory systems, such as harnessing the
adaptive immune response towards immune self-tolerance
in the treatment of autoimmune disease or to prevent graft
rejection, or alternatively to prime aggressive immunity
towards cancer cells; (iii) creation of an artificial transient
microstroma as a supportive niche for endogenous repair,
applicable following trauma or in age-related degenerative
diseases, or as a supportive matrix for cells used in cell-
based therapy. We consider the value of the targeted
delivery of a stem cell growth factor called "leukaemia
inhibitory factor" (LIF) in the context of LIF's biologic
properties which are directly relevant to the treatment of
multiple sclerosis (MS).
1.1 Why Choose LIF as a Therapeutic?
Why LIF? Firstly, LIF is a multi-functional cytokine that is
involved in regulating the plasticity of a genome [for
example, 1, 2]. Such plasticity plays a central role through‐
out life because it permits the progressive stages of lineage
development within the different biological systems of an
organism. Plasticity is linked to micro-environmental cues
during a cell’s transit through fate decision forks, for
example during haematopoiesis, to provide the different
cell types that make up a healthy haematopoietic system
[3]. LIF's role in regulating genomic plasticity is not only
central for development, but also for the recruitment of
endogenous stem cells and precursor cells during the
maintenance, repair and remodelling of mature tissues.
Examples include bone remodelling in response to stress,
and the increase in muscle mass in response to work load.
The plasticity of a genome supported by LIF is linked to
"pioneer factors". These are transcription factors able to
access specific genes within compacted DNA in response
to growth factor signalling. Notably, the loss of the LIF
receptor, gp190, is early embryonic lethal. Indeed, LIF
signalling is critically involved in the full reprogramming
control of biological systems, which is achieved by only a
few key control factors that impact a small number of nodes
(five or less) [4]. Overall, LIF is highly attractive as a
therapeutic, with special relevance to the regenerative
medicine arena, where harnessing of LIF using nanotech‐
nology will progress the move towards cell-free therapeu‐
tics.
As a therapeutic, the second attraction of LIF is its role in
the adaptive immune system. Here, T lymphocytes, each
expressing a unique antigen-specific receptor, provide the
full repertoire of antigen recognition of an individual plus
the exquisite specificity of the adaptive immune response.
Failsafe mechanisms ensure that the power of an immune
attack is restricted to invading pathogens. Should these
mechanisms malfunction, then an immune attack against
the body's own tissues will lead to autoimmune disease and
possibly even death. An autoimmune protective role for LIF
has recently been discovered [5-8]. Here, LIF supports self-
tolerance by supporting self-reactive tolerogenic regulato‐
ry T lymphocytes (Treg). Since an activated Treg releases
more LIF, self-sustaining populations of self-reactive Treg
are perpetuated.
1.2 The LIF / IL-6 axis - A Critical Node in Immunity that Defied
Dogma
In the adaptive immune system, the finding that LIF, in
addition to promoting Treg and self-tolerance, also directly
opposes interleukin-6 (IL-6) [8] is of profound importance.
IL-6 induces inflammatory immunity including immunity
driven by TH17 cells which, when inappropriately activat‐
ed, are strongly linked to autoimmune disease. To be able
to harness the LIF / IL-6 axis in order to reset autoimmune
self-tolerance would achieve an ultimate goal in autoim‐
mune therapies.
Dogma blocked initial attempts to publish the LIF / IL-6 axis
in Treg / TH17 immunity. Flawed reasoning argued that,
since LIF belongs to the IL-6 cytokine family, then LIF must
activate the same pathways and genes as IL-6. Biased
judgement obscured the discovery that opposing feed-
forward loops of gene expression are activated by LIF versus
IL-6. The expression of gp190, the LIF-specific sub-unit of
the LIF receptor, provides a pivotal mechanism for the axis
(Figure 1C) [7, 8]. It is relevant to note that transforming
growth factor beta (TGFβ) is required for T cell activation.
This raises the question, how does TGFβ fit with the LIF /
IL-6 axis? In experiments conducted by Gao et al., although
activated TGFβ was required for both Treg and TH17
lineage maturation, it was LIF, versus IL-6, that imposed the
mutually exclusive lineage-specificity [8]. Thus, TGFβ acts
in combination with LIF, or IL-6, but does not specify
lineage.
The field is young. Do other systems also operate under
a LIF / IL-6 axis for cell fate in development, for exam‐
ple,  during  endogenous  repair?  If  yes,  then  the  com‐
bined properties of LIF (reparative and tolerogenic) might
cooperate  in  vivo  with  Treg,  playing  a  dual  role  -  one
immune,  for  self-tolerance  and  the  second,  non-im‐
mune, for repair. Moreover, given its proposed mechanis‐
tic simplicity - based on receptor competition between the
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two cytokines [7,  9-10] -  the LIF /  IL-6 axis may repre‐
sent a previously unrecognized mechanism at the core of
stemness.  This  could  even  extend  to  asymmetric  divi‐
sion, given that NANOG enhances LIF signal transduc‐
tion [2]. Although clearly speculative, these predications
anticipate  the  targeted  delivery  of  LIF  as  a  powerful
nanotherapeutic  platform  relevant  to  a  wide  range  of
indications.
Figure 1 depicts the position of genomic plasticity in
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The Ying-Yang images convey that genomic plasticity is central to homeostasis within the whole multicellular organism (A) and in the mature adaptive
immune system (B). Both require cell proliferation to provide numerical sufficiency for specific functions. In adaptive immunity rare antigen specific cells
must amplify many thousand-fold when activated by cognate antigen. Proliferation must be linked to genetic plasticity, permissive for cell lineage differen‐
tiation. As cells differentiate, they lose plasticity (i.e., they move towards the perimeter of the Ying-Yang, plasticity being at the transit zone between stemness
and differentiation). For the adaptive immune response, the rapidly proliferating CD4+ lymphocytes responding to antigen must acquire the appropriate
phenotype that is required to orchestrate a host defence. This is guided by cues from the surrounding microenvironment; for example, the inflammatory
cytokine IL-6 guides the maturation of cells towards the TH17 lineage. In MS, inappropriately activated "rogue" myelin-specific TH17 cells enter the CNS and
attack myelin, causing demyelination and compromising survival of the affected nerves. Moreover, differentiated TH17 cells release IL-17 - an inflammatory
cytokine that directly suppresses myelin repair.
LIF's involvement with genomic plasticity underpins its therapeutic potential. In (A), the stemness compartment provides for the maintenance, repair and
remodelling of tissues throughout life - though the compartment size decreases over time. Leukaemia inhibitory factor (LIF) promotes the stemness
compartment and genetic plasticity. In (B), LIF guides the tolerogenic lineage of lymphocytes (Treg), which are required to prevent an autoimmune attack.
LIF is both reparative and tolerogenic, providing a uniquely powerful therapeutic for multiple indications, both within the regenerative medicine space, and
to treat autoimmune disease. By overcoming issues of stability and pleiotrophy, nanotechnology can harness the value of LIF for specific indications by targeted
delivery to provide a designer therapeutic.
Figure 1C depicts the LIF / IL-6 axis that guides Treg (LIF) versus TH17 (IL-6) lineage differentiation of the naive CD4+ lymphocyte responding to cognate
antigen. Initially, there are common features early in differentiation but genetic hardwiring of phenotype develops, which is imposed by epigenetic changes.
The axis is critically determined by the LIF-specific receptor subunit "gp190". Heterodimers gp190/gp130 transmit LIF signals to the genome, inducing the
transcription of both LIF and gp190 genes, as well as the forkhead-box-3 transcription factor, "FOXP3". FOXP3 function is absolutely required for Treg and
self-tolerance. Lack of FOXP3 results in death due to overwhelming autoimmune disease. In contrast to LIF, homodimers of gp130/gp130 transmit IL-6 signals
to the genome, suppressing gp190 and thus, rendering the cells blind to extracellular LIF. IL-6 increases the transcription of retinoic-acid-receptor-related-orphan-
receptor gamma-t, shortened to "RORgt", which is required for TH17 lineage differentiation. Notably, IL-6 also strongly induces transcription of the E3-ligase
gene "MARCH7". MARCH7 is involved in the degradation of the gp190 protein that, together with a shutdown of gp190 transcription, further reduces the
ability of the lymphocytes to respond to LIF, reinforcing polarization to TH17. The finding that nanoparticle-mediated delivery of LIF to CD4+ T cells opposes
IL-6 and prevents RORgt induction is of profound significance for autoimmune disease therapy. The LIF-NP appears to recapitulate endogenous mechanisms
of opposing TH17 immunity in favour of antigen-specific Treg induction. Once established, the epigenetically mature Treg perpetuates self-tolerance. Arrows
indicate the sites that are sensitive to treatment with LIF. The star in (C) indicates the use of targeted LIF-NP to promote Treg.
Figure 1. Some Biological Sites Available to Manipulation by LIF Therapy
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immune system (Figure 1B), and at the LIF / IL-6 axis during
CD4+ lymphocyte maturation (Figure 1C). Sites that are
available for manipulation by LIF are indicated. These sites
can be accessed using nanotechnology and we next present
the nano-formulation of LIF which permits its use as a
therapeutic.
2. Therapeutic Nanoparticles and the Adaptive Immune
system
A short half-life normally attenuates cytokine activity in
vivo [11] and this needs to be overcome when exploiting
cytokines for therapy. Cytokine half-life may be prolonged
by modifying the cytokine structure, for example by the
attachment of fusion molecules such as polyethylene glycol
(PEG) [12] or humanized antibody fragments [13], or by
genetic engineering to create a glycosylated cytokine. An
alternative approach is cytokine gene therapy. This uses
viral constructs, including lentivectors, which actively
integrate into genomic DNA without requiring cell repli‐
cation and provide a stable, long-term expression of the
gene. However, these approaches lack the sophisticated
levels of control that are available when applying nano‐
technology. Furthermore, none of them replicate the
physics of delivery on a nanoscale, where potency of cargo
is massively increased.
2.1 The LIF-PLGA Nanoparticle Prototype
The development of the LIF-PLGA nanoparticle (LIF-NP)
was based on strategic reasoning. The polymer poly(lac‐
tide-co-glycolide) (PLGA) is already approved by the FDA
for drug delivery applications due to its safety, excellent
biocompatibility and “tunable” release rates. In nanoparti‐
culate form, PLGA decorated with functional avidin
groups on the nanoparticle surface, enables the modifica‐
tion of this surface through the robust attachment of
biotinylated ligands such as PEG [14], T cell-stimulating
antibodies [15], or T cell-targeting antibodies [16]. This
technology is well-suited towards stimulation and manip‐
ulation of immune cell development through (i) the
presence of T cell-specific cell surface molecules that can be
targeted by antibodies; (ii) on the nanoparticle, presenta‐
tion of multiple targeting ligands per nanoparticle, ensur‐
ing high valency and avidity of contact with targeted
cellular ligands; and (iii) delivery of multiple cytokine
molecules per biorecognition event to ensure a relatively
high concentration of cytokine precisely within the micro‐
environment of the targeted cell, whilst avoiding systemic
exposure to the therapeutic cytokine. Figure 2 illustrates a
range of nano-structures, together with the prototypic LIF-
PLGA nanoparticle.
2.2 Does it Work? Is Targeting Necessary? What Dose of LIF Is
Delivered? In Vivo?
For the prototype, the end point of success was the dem‐
onstration of (i) target-specific delivery of cytokine; (ii)
retained bioactivity specific to the released cytokine cargo;
and (iii) a biological response specific to the targeted cells.
All of these benchmarks were met when exploiting the LIF /
IL-6 axis as a stringent model to prove bio-efficacy in a
study by Park et al. [17]. When targeted to CD4+ T lym‐
phocytes, LIF-NP, versus IL-6-NP, provided extracellular
cues able to control T cell maturation via the lineage-
determining master genes, FOXP3 (Treg) and RORγt
(TH17), respectively [18-22]. Cell targeting was necessary
for the biological response and demonstration of being able
to harness a fate decision in CD4+ T lymphocytes, where
there is exquisite specificity for antigen combined with
immune memory, led to the highly relevant question, can
LIF-NP directly oppose the IL6-driven pathway? If yes, then the
targeted delivery of LIF by LIF-NP may guide tolerogenesis
- even in the face of a local inflammatory IL-6-rich micro‐
environment as occurs in TH17-linked autoimmune
activity. The actual dose of cargo being delivered when
using nanoparticles is extremely low: one milligram of
PLGA nanoparticles carries around one nanogram LIF
cargo. However, LIF, when formulated as LIF-NP, was
>1000-fold more potent than soluble LIF. When delivered
as LIF-NP, 200pg LIF opposed the effect of 20,000pg soluble
IL-6, preventing RORγt induction. Indeed, a recent math‐
ematical model estimated that the potency of a drug or
cytokine could be increased by several orders of magnitude
when the cytokine is delivered via a biodegradable particle
targeted to T cells [23]
The next relevant question was, do the LIF-NP work in
vivo? The answer is yes. Firstly, CD4-targeted LIF-NP
biased the in vivo immune response towards tolerance, as
measured in transgenic GFP-FOXP3 mice. The relative
numbers of antigen-specific FOXP3+CD4+ T cells increased
following the donor-specific transfusion (DST) of LIF-NP-
coated cells targeted to CD4. This effect was in marked
contrast to the use of IL-6-nano-treated lymphocytes in the
DST system, where no increase of FOXP3+ cells occurred.
Thus, the expansion of antigen-specific FOXP3+ cells was
confirmed as being due to the specific bioactivity of LIF-
nano and not a function of the delivery system itself. A
more stringent test used mismatched vascularized heart
allografts in mice. Here efficacy was also seen with LIF-NP
treatment prolonging activity of the beating-heart graft.
Overall, the Park study [17] showed that the LIF / IL6 axis
can be recapitulated in T cells treated with LIF-NP / IL6-
NP, where the nanoparticulate therapeutic approach is
underpinned by the targeted, controlled, sustained release
of bioactive LIF, or IL-6, in low physiological doses within
the precise microenvironment of the target cell. By target‐
ing CD4+ T lymphocytes, the immune response of the fully
immune competent mouse was manipulated. By extrapo‐
lation, selective targeting of other systems for specific
biological responses would similarly produce target-
specific effects - as is next presented for myelin repair where
the target is the oligodendrocyte precursor cell that
expresses neuroglial-2 (NG2) antigen and LIF-NP are
targeted to NG2.
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Top panel: There are various nano-delivery systems but they can be generally classified under five broad categories, which are illustrated from left to right:
(i) vesicular NP (including liposomes, micelles and multilamellar systems); (ii) solid biodegradable or matrix-based NP (a classic prototypical example is
polylactide-co-glycolide) (PLGA) nanoparticles or organometallic NP such as gold NP; (iii) macromolecular systems, such as branching and iterative polymers,
an example of which are dendritic polymers such as polyamidoamine (PAMAM) dendrimers; (iv) supramolecular assemblies involving the self-assembly of
branched or linear chain polymers into a stimuli-responsive nanoparticle structure; and (v) hybrid systems, such as core-shell nanoparticles, with a matrix/
biodegradable core and lipid shell. Matrix and vesicular systems are ideally suited for LIF delivery. For example, biodegradable matrix systems can facilitate
the sustained release of LIF, whereas liposomal systems are relatively unstable for LIF delivery, depending on the lipid composition. Hybrid nanogels enable
a combinatorial delivery because of the multiple components that allow the encapsulation of LIF and other molecules for synergistic delivery to the site of
interest. Lower panel: Generally, all of the NPs are modular in nature and can be surface modified for targeting different cell types. Targeting T cells, such as
CD4+ T cells, using antibodies to CD4 (bottom left) for delivery of LIF or IL-6, or entrapment in tumour vasculature for delivery of small molecule drugs and
cytokines. An important application is the delivery of siRNA and blood-brain barrier (BBB) penetration. Use of whole body imaging to track fluorochrome-
tagged PLGA nanoparticles in a mouse confirms that nanoparticles cross the BBB and enter the brain parenchyma after intra-nasal delivery. This is shown in
the image bottom right, blown up to reveal the anatomy of the brain and location of the labelled nanoparticles within the brain parenchyma: image pixilation
results from the blow-up of the original image.
Figure 2. Optional Nanoparticle Formulations of LIF
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3. Multiple Sclerosis: A Case for Nanomedicine
Multiple sclerosis (MS) is a T cell-mediated inflammatory
demyelinating disease of the human central nervous
system (CNS). It is the most common disease of the CNS
that affects young adults. Onset occurs between 20 - 40
years of age and the worldwide incidence is 2.5 million,
with 2,500 cases being diagnosed each year in the UK alone.
Scotland has the highest incidence of MS worldwide, with
1 in 170 women on the Orkney Islands being affected.
Although the cause remains unknown, predisposing
factors include being female and Caucasian, whilst the
higher incidence in the northern and southern hemispheres
suggests a link to vitamin D deficiency due to low sunlight,
vitamin D being important in Treg-mediated self-tolerance
[24-26]. For the patient, MS is a disease that, in its latter
stages, is perceived to be worse than death.
3.1 MS is Caused by Both Autoimmunity and Demyelination of
Nerve Axons
Treatment for MS is highly challenging. Not only must
autoimmunity be reset to self-tolerance but also the
structural damage to the demyelinated nerves must be
repaired. The two are inextricably linked, since it is the
immune-mediated demyelination of nerve axons that
causes the neurological symptoms of MS. The loss of
myelin's function for efficient electrical conductance along
nerve axons, combined with the loss of myelin-derived
metabolic support for the axon, eventually leads to the
death of the nerve itself. In most cases, MS initially develops
with alternating relapses and remissions of symptoms that
reflect repeated waves of autoimmune neuro-inflamma‐
tion. However, over time, nerve death increases, leading to
irreversible progressive disease. In a few cases, the disease
is immediately progressive. In the relapsing form, early
remissions occur because the demyelination can be re‐
paired endogenously (remyelination), restoring fast nerve
axonal impulse conduction, together with protection and
support of the axon. However, this myelin repair is
inefficient and, over time, fails. Thus, although immuno‐
suppressive therapies can reduce the probability of new
relapses [27, 28], the progressive effects of demyelination
remain untreatable.
EVIDENCE FOR TH17 / IL17 / IL-6 ACTIVITY IN MS
(i) The immune and neurotoxic effects of IL17 towards NG2+ glia provide crucial links the inflammatory and neurodegenerative aspects of MS.
KANG ET AL 2013 [31]
(ii) Infiltrating IL-17+ T cells are associated with active human disease.
TZARTOS ET AL 2008 [45]
(iii) In vitro treatment of CD4+ T cells from MS patients with LIF boosts Treg
JANSSENS ET AL 2014 [46]
(iv) BBB-endothelial cells (BBB-EC) IL-17 receptors in MS lesions; IL17 disrupts BBB tight junctions; TH17 cells transmigrate across BBB-ECs and
promote CNS inflammation through CD4+ lymphocyte recruitment.
KEBIR ET AL 2007 [47]
(v) EAE model: increased Treg : TH17 ratio correlates with recovery of acute EAE.
ALMONDA ET AL 2011 [48]
(vi) EAE model: soluble LIF opposes TH17 immunity, reduces disease severity.
CAO ET AL 2012 [33]
(vii) IL-6:
• TH17 immunity requires IL-6. BETTELLI ET AL 2010 [49]
• EAE requires IL-6 but IL-6-null mouse that is resistant to EAE becomes sensitive to EAE if supplemented with exogenous IL-6. OKUDA ET
AL 1999 [50]
• EAE: site-specific IL-6 focuses inflammatory immunity in CNS QUINTANA ET AL 2009 [51]
MYELINATION
(i) EAE model: CNS-targeted LIF limits autoimmune-mediated demyelination.
SLAETS ET AL 2010 [53]
(ii) Demyelination model: delivery of LIF-viral increases reparative remyelination
DEVERMAN AND PATTERSON 2012 [52]
(iii) Demyelination model: delivery of LIF-NP increases reparative remyelination.
RITTCHEN ET AL [36]
Table 1. Multiple Sclerosis: evidence for a LIF/IL-6 axis in MS pathogenesis
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3.2 Can the Endogenous Pathway for Myelin Repair Be
Harnessed to Rescue Neurons? A Role for LIF
Since the removal of myelin renders axons metabolically
non-viable,  there  is  an  intense  need  to  understand  the
mechanisms by which myelin repair either occurs or fails.
If LIF proves reparative, then therapy that uses LIF-NP
becomes of prime importance. To date, we know that the
natural repair pathway for remyelination of demyelinated
axons involves endogenous oligodendrocyte precursor cells
(OPCs). OPCs respond to demyelination by proliferation
and  migration  to  the  area  of  damage;  here  they  then
differentiate into mature oligodendrocytes (OD) able to
repair myelin. However, in MS, this repair process fails [29,
30]. This is partly due to becoming exhausted by the repeated
attacks of demyelination and partly because of a critical
block in the progression of OPCs to fully differentiated
mature OD [31]. Can this maturation block be overcome?
Accruing evidence indicates a central role for LIF.
LIF naturally occurs in the CNS and is implicated in both
primary myelination and remyelination. LIF is released by
astrocytes during activity-dependent cross-talk between
axons OPCs and OD, during normal myelination [32]. It is
known that treatment of inflammatory demyelination in
experimental allergic encephalomyelitis (EAE, a model of
MS) with soluble recombinant LIF or lentiviral overexpres‐
sion of LIF in the CNS improves clinical outcome and
decreases pathology. Moreover and unexpectedly, LIF is
the underlying mechanism by which transplanted neural
precursor cellS (NPC) reduce EAE symptoms [33]. It was
shown that NPC-derived LIF opposed the differentiation
of pathogenic TH17 cells in vivo - indeed, NPC cells can be
replaced by recombinant LIF alone.
A. The pictorial resume of in vitro data shows that, when targeted to NG2+ OPC, the delivery of LIF by nanoparticles generates a potent biological response.
Picomolar doses of the delivered LIF to OPC induce their maturation to myelin-competent oligodendrocytes. The effect requires cell targeting, rather than the
aggregation of the cell surface NG2, or leakage of LIF from the nanoparticles. B. In vivo, the therapeutic effect of LIF-NP was confirmed in a model of chemically
induced focal demyelination (mouse corpus callosum): 8 days after lesioning nanoparticles were introduced into the lesion. At 25d, the mice were culled and
the remyelinated axons were measured by transmission electron microscopy. C. Both the thickness of myelin and the number of myelinated axons were
significantly increased in the NG2 targeted LIF-NP group, whilst the targeted empty-NP did not differ from the untreated controls or non-targeted LIF-NP
controls [36].
Figure 3. LIF-NP Promote Myelin Repair
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In  marked  contrast  to  LIF,  interleukin-17  (IL17)  -  the
signature  cytokine of  inflammatory TH17 cells  that  are
present in MS lesions - has adverse effects on myelination
[31]. Not only is IL-17 strongly inhibitory for the matura‐
tion of neuroglial-2 (NG2)-positive OPC to myelin synthe‐
sizing OD, but IL17 also reduces OPC survival. Thus, a single
cytokine - IL-17 - provides a direct link between neuroin‐
flammation and neurodegeneration in MS. This brings us
back to the LIF (Treg) / IL-6 (TH17) axis and LIF's ability to
oppose inflammatory TH17 cells. If there is a LIF / IL-6 axis
in MS - as suggested by the evidence listed in Table 1 - then
LIF's role in promoting reparative remyelination provides
a route to treat both autoimmunity and demyelination in MS.
3.3 A Place for LIF-Nanotherapy As a Treatment Option for MS
A wide range of immunosuppressive treatment options are
approved for the various types and stages of MS. These
reduce the autoimmune attack and current disease modi‐
fyng therapies include beta-interferons, copaxone, fingoli‐
mid, nataluzimab and BG-12 (dimethyl fumarate). A recent
addition is the monoclonal anti-CD52 antibody, alemtuze‐
mab (previously known as CAMPATH-1H). However, all
of these treatments have unwanted side effects. For
alemtuzumab, secondary autoimmune disease is common.
Alemtuzumab is a lymphodepleting antibody that spares
bone marrow stem cells. In MS, it is used as part of a
regimen of an induction therapy that first aims to deplete
the entire immune system of the patient and, thereafter,
allow the immune system to re-boot self-tolerance during
homeostatic recovery. Initially, the patient is at high risk of
infection. Thereafter, recovery is associated with signifi‐
cantly reduced disease. However, in a third of patients,
secondary autoimmunities develop, most commonly of the
thyroid. These appear to be driven by TH17 activity [34,
35], where IL-21 is produced by TH17 cells and drives IL-17
production. Since LIF opposes TH17 immunity, the concept
of dual therapy – i.e., treating with alemtuzumab, followed
by LIF-NP during homeostatic recovery phase - may
enhance self-tolerant immunity and avoid secondary
autoimmunity as the recovering T cell repertoire matures.
But, a far more important role for LIF-NP in MS thera‐
py  is  myelin  repair,  which  is  currently  untreatable.
Rittchen et al. [36] showed that, in vivo, LIF-NP targeted
to  OPC increased the  quality  of  myelin  repair  by both
increasing numbers of  remyelinated axons and increas‐
ing  thickness  of  remyelinated  axons.  This  proof  of
principle  revealed two key points:  (i)  LIF that  is  deliv‐
ered  in  the  form  of  PLGA  nanoparticles  is  bioactive
within  the  brain  (Figure  3)  and  (ii)  a  remarkably  low
concentration  -  picomolar  range  -  of  LIF  induces  a
This shows how targeted LIF-nanotherapy might oppose disease-driving inflammatory TH17 lymphocytes, whilst simultaneously promoting the remyeli‐
nation of demyelinated axons. IL-6 signals through the gp130/gp130 homodimers of the IL-6 receptor to drive differentiation of inflammatory TH17 cells,
which are pathogenic in clinical MS. This contributes to axonal demyelination (left panel). The right panel anticipates that LIF, formulated as PLGA-NP and
targeted to both CD4+T cells and NG2+ OPC, will promote endogenous Treg within the CNS and promote remyelination of demyelinated axons.
The reasoning behind the use of LIF-NP to treat MS is the two-fold proof of principle [17, 36]: (i) a single dose provides the sustained paracrine-type delivery
of LIF over several days, allowing time for epigenetic stabiliztion of biological effect, e.g., induced Treg; (ii) since Treg releases LIF, the effect of transient
therapy using LIF-NP will become sustained by endogenous Treg that reacts with myelin - releasing more LIF. Thus, LIF-NP provides a drug-free, cell-free,
and viral-free route to treat MS by harnessing two endogenous pathways, one tolerogenic, the second reparative, that - once active - are mutually supportive
[54, 55].
Figure 4. A pictorial summary of the LIF/IL-6 axis as it relates to MS
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therapeutic  remyelination effect.  The in  vivo  remyelina‐
tion study design was simplified by delivering LIF-NP
directly  into  the  demyelinated  lesion  of  the  corpus
callosum. The next step is to establish a route for delivery
of  the  targeted  LIF-NP  suitable  for  patients  and  that
crosses  the  blood-brain-barrier  (BBB).  Given  that  the
PLGA platform used for LIF-NP is the same as that used
by BIND therapeutics (already approved by the FDA and
in  clinical  trial  to  deliver  cytotoxic  agents),  safety  is
unlikely to be an issue. This is especially the case, given
the low dose of  LIF and LIF's  global  reparative role at
physiological levels. Considering the BBB, although this
is defective in active MS lesions, sites that have become
quiescent may be accessed by intranasal delivery. This is
an  optional  delivery  route  that  crosses  the  BBB  at  the
cribiform plate at  the back of  the nasal  cavity [37]  and
has  been successful  for  PLGA nanoparticles  (Figure  2).
Alternatively,  incorporation of the simil-opiod "7g" into
the nanoparticles has been shown to promote uptake into
the  CNS  via  the  opioid  receptor  following  systemic
delivery [38].
As a treatment for MS, LIF has three values: (i) opposition
of TH17 immunity, (ii) repair of demyelinated axons and
(iii) promotion of self-sustaining self-tolerance to myelin
(Figure 4). By treating both autoimmunity and demyelina‐
tion, LIF-NP provides a drug-free, cell-free, viral-free
option to current strategies of treating MS. It is worth
noting that, for myelin repair, there are two candidate
therapeutics that are under trial: the repurposed antihista‐
mine, clemastine fumarate [39], and a monoclonal antibody
against Lingo-1 [40]. Neither of these provide the synergis‐
tic values of LIF-NP therapy.
4. Clinical Perspective
When considering LIF-nanotherapy in terms of translation
the clinic, the two immediate considerations are (i) route of
delivery and (ii) de-risking. Firstly, route of delivery of LIF-
NP is linked to the therapeutic aim. For modulating the
immune  response  in  autoimmune  disease,  systemic
delivery to circulating lymphocytes via the intravenous
route is one option. Alternatively, direct delivery to specific
sites - for example, the inflamed joint - may be selected. For
skin conditions, such as psoriasis,  a topical formulation
would be appropriate. For treatment within the CNS, the
challenge of overcoming the BBB becomes less of an issue
with the success of intra-nasal delivery. Here, nanoparticle-
formulated cytokines and growth factors are highly relevant
to the treatment of both neurodegenerative and demyelinat‐
ing diseases, with advantages over the cell-based therapeu‐
tic  approach.  Nanomedicine  delivering  biologics  is
imminent, following on the heels of nano-based platforms
for delivery of drugs that are currently in clinical trials.
Secondly, in addition to standard pharmaceutical de-
risking, safety is the central consideration for nanomedi‐
cine. As novel nanotherapeutic devices are developed,
biocompatibility is crucial and biodegradation is a major
advantage. This links to endogenous systems that can be
harnessed by transient therapy, avoiding the potential of
long-term physiological distortion due to the therapeutic
(e.g., as may occur with viral-mediated delivery). A
combination of nanotechnology with biological systems in
vivo requires an understanding of the "deep" biology of the
target and how this might be impacted by the candidate
nanotherapeutic in holistic terms. The need for unifying
expertise across the disciplines in order to maximize
therapeutic gain, whilst avoiding any potential risk, is
paramount. Such specialized de-risking will run alongside
established de-risking strategies for a novel biologic
therapeutic. For PLGA-based technology, approval by the
FDA and the current clinical trials being run by BIND
Therapeutics are encouraging.
5. Conclusion
The therapeutic potential of LIF enabled by formulation as
PLGA nanoparticles extends to tolerogenesis [17]; support
of cell and tissue grafts [41 - 43]; and repair of myelin [36].
Untested is the ability of LIF-NP to synergise with other
nanotherapeutics, though LIF-NP when combined with
XAV939-NP (a wnt signalling inhibitor) revealed that
neural precursor cell lineages are sensitive to manipulation
[44]. Although arguably premature as an overview, the
progress of LIF-NP in nanomedicine is well underway and
future major indications include the neurodegenerative
diseases where LIF may reduce inflammatory pathogenesis
and be prosurvival for neurons, for example in Parkinson's
and Alzheimer's Diseases; also the retinopathies, where
LIF's neurogenic and neuroprotective properties may
reduce loss of vision by supporting the retinal pigment
epithelium of the eye.
Finally, the question arises - can LIF-NP act on an endoge‐
nous stem and precursor cells for tissue repair? This would
provide a simple defined route to reduce or even replace
the need for exogenous delivery of therapeutic stem cells
in regenerative medicine.
6. Dedication
We dedicate this overview to Paul Patterson (1944-2014),
who first recognized LIF's role in neuro-immunity and,
more recently, identified maternal IL-6 as being linked to
the risk of autism and schizophrenia in offspring, two
amongst many of Paul's groundbreaking discoveries now
being pursued worldwide.
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